Lipids Research

Phase I study of novel cholesterol management vaccine published

Published in Vaccine Weekly, August 20th, 2003

Research published in the journal Atherosclerosis supports the feasibility, immunogenicity, and safety of an experimental vaccine approach to raising HDL cholesterol under development by AVANT Immunotherapeutics.

The publication details results of a dose-ranging, placebo-controlled Phase I human trial and extension study of AVANT's cholesterol ester transfer protein (CETP) vaccine, CETi-1. This investigational vaccine is designed to elicit antibodies that bind and inhibit the activity of CETP, blocking the ability of that protein to transfer cholesterol from HDL to LDL and thus causing HDL cholesterol levels to rise.

A Phase II trial of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry